ECSP003625A - HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALOPROTEINASE INHIBITORS - Google Patents
HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALOPROTEINASE INHIBITORSInfo
- Publication number
- ECSP003625A ECSP003625A ECSP003625A ECSP003625A EC SP003625 A ECSP003625 A EC SP003625A EC SP003625 A ECSP003625 A EC SP003625A EC SP003625 A ECSP003625 A EC SP003625A
- Authority
- EC
- Ecuador
- Prior art keywords
- diseases
- compounds
- methods
- acid compounds
- compounds useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000011159 matrix material Substances 0.000 title 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 2
- 208000025865 Ulcer Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 231100000397 ulcer Toxicity 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010064996 Ulcerative keratitis Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 201000007717 corneal ulcer Diseases 0.000 abstract 1
- 230000010339 dilation Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000005747 tumor angiogenesis Effects 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Los compuestos de la fórmula (gráfico), son útiles para inhibir las enzimas de metaloproteinasa de matriz en animales, y evita y trata las enfermedades que resultan de la quebradura de tejidos conectivos. Además se decsriben métodos para la preparación de tales compuestos, composiciones farmacéuticas incluyendolos, y métodos de tratamiento de enfermedades en los cuales las metaloproteinasas de matriz son involucradas incluyendo la esclerosis múltiple la ruptura de placa de la arteriosclerosis, la restenosis, la aneurisma aórtica, la cardiopatías, las enfermedades periodontales, úlcera de cérnea, quemaduras, úlceras decubial, úlceras o heridas crónicas, metástasis de cáncer, angiogénesis de tumor, osteoporosis, reuma o osteoartritis enfermedad renal, dilatación ventricular izquierda, u otras enfermedades autoinmune o inflamatorias de la invención de leucocitos en el tejido.The compounds of the formula (graph) are useful for inhibiting matrix metalloproteinase enzymes in animals, and prevents and treats diseases resulting from breakdown of connective tissues. In addition, methods for the preparation of such compounds are described, including pharmaceutical compositions, and methods of treating diseases in which matrix metalloproteinases are involved including multiple sclerosis, rupture of arteriosclerosis plaque, restenosis, aortic aneurysm, heart disease, periodontal diseases, corneal ulcer, burns, decubial ulcers, chronic ulcers or wounds, cancer metastases, tumor angiogenesis, osteoporosis, rheumatism or osteoarthritis kidney disease, left ventricular dilation, or other autoimmune or inflammatory diseases of the invention of leukocytes in the tissue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003625 ECSP003625A (en) | 2000-08-17 | 2000-08-17 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALOPROTEINASE INHIBITORS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003625 ECSP003625A (en) | 2000-08-17 | 2000-08-17 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALOPROTEINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003625A true ECSP003625A (en) | 2000-11-24 |
Family
ID=42041230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003625 ECSP003625A (en) | 2000-08-17 | 2000-08-17 | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALOPROTEINASE INHIBITORS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP003625A (en) |
-
2000
- 2000-08-17 EC ECSP003625 patent/ECSP003625A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY26302A1 (en) | HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALOPROTEINASE INHIBITORS LAW 17,164 | |
| JOP20230035A1 (en) | APOL1 inhibitors and their uses | |
| CY1115870T1 (en) | 1,2,4-OXIADEZOLO Benzoic Acid Compounds and Their Use for Non-Nutritional Suppression and Illness Therapy | |
| WO2001042231A3 (en) | Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors | |
| IS2114B (en) | Quinazoline derivatives to treat tumors | |
| NZ534891A (en) | Selective dipeptide inhibitors of kallikrein | |
| NO982185L (en) | Novel macrocyclic compounds as metalloproteinase inhibitors | |
| DE69728375D1 (en) | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | |
| ATE361300T1 (en) | DERIVATIVES OF HETEROARYLNITRIL COMPOUNDS | |
| CY1108748T1 (en) | USE OF IL-18 INHIBITORS FOR TREATMENT AND / OR PREVENTION OF REGULAR VASCULAR DISEASES | |
| ES2191069T3 (en) | DIARIL-2- (5H) -FURANONAS AS COX-2 INHIBITORS. | |
| KR20090040323A (en) | Compositions and Methods for the Treatment of Mucositis | |
| BR9815596A (en) | Compound, pharmaceutical composition, method of treating inflammatory diseases and method of treating condition or disease mediated by mmps and / or tnf and / or agrecanase | |
| BR9712794A (en) | Compounds for and a method of inhibiting matrix metalloproteinases | |
| CY1108992T1 (en) | USE OF HYALURONIC ACID FOR PREPARATION OF COMPOSITIONS FOR THE THERAPEUTIC TREATMENT OF ORAL TRAUMATIC DISEASES | |
| DE69619865D1 (en) | AROMATIC KETO ACID AND THEIR DERIVATIVES AS INHIBITORS OF THE MATRIX METALLOPROTEINASE | |
| AP2001002037A0 (en) | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases. | |
| IL174525A0 (en) | Medicamentously targeted local lipolysis | |
| PT1562954E (en) | CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DEMANDING DISEASE I.A. | |
| ES2189165T3 (en) | NEW MACROCICLIC COMPOUNDS AS METALOPROTEASA INHIBITORS. | |
| Corbitt et al. | Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors? | |
| Weber et al. | Renal cell carcinoma bone metastasis—elucidating the molecular targets | |
| Geng et al. | Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model | |
| SE0002739D0 (en) | New use | |
| DK1441714T3 (en) | Combinations comprising a selective cyclooxygenase-2 inhibitor |